# Chemours Co: Form 10-Q for the period ended Jun 30, 2017

- Company: [Chemours Co](/companies/cc.md) (CIK 1627223)
- Form: 10-Q
- Filed: 2017-08-03
- Accepted by EDGAR: Aug 3, 2017, 16:38 ET
- Period: 2017-06-30
- Accession: 0001564590-17-015399
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1627223/000156459017015399/cc-10q_20170630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1627223/000156459017015399/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Gross profit | 3 months, 2017-04-01 to 2017-06-30 | $441.0m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2017-01-01 to 2017-06-30 | $799.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2017-04-01 to 2017-06-30 | $21.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2017-01-01 to 2017-06-30 | $40.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2017-04-01 to 2017-06-30 | $157.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2017-01-01 to 2017-06-30 | $301.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2017-04-01 to 2017-06-30 | $55.0m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2017-01-01 to 2017-06-30 | $106.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-04-01 to 2017-06-30 | $64.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2017-01-01 to 2017-06-30 | $87.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-04-01 to 2017-06-30 | $161.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2017-01-01 to 2017-06-30 | $311.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-04-01 to 2017-06-30 | $0.84 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2017-01-01 to 2017-06-30 | $1.64 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-04-01 to 2017-06-30 | $0.87 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2017-01-01 to 2017-06-30 | $1.69 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-04-01 to 2017-06-30 | 191,126,639 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2017-01-01 to 2017-06-30 | 190,142,873 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2017-01-01 to 2017-06-30 | $224.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2017-01-01 to 2017-06-30 | $138.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2017-01-01 to 2017-06-30 | $11.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2017-06-30 | $1.53bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-06-30 | $3.44bn | us-gaap:AssetsCurrent |
| Total assets | at 2017-06-30 | $7.05bn | us-gaap:Assets |
| Current liabilities | at 2017-06-30 | $1.75bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-06-30 | $6.48bn | us-gaap:Liabilities |
| Long-term debt | at 2017-06-30 | $4.06bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2017-06-30 | $14.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2017-06-30 | $567.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 66,846 characters.

### Introduction

Management’s discussion and analysis, which we refer to as “MD&A”, of our results of operations and financial condition supplements the unaudited interim consolidated financial statements and related notes included elsewhere herein to help provide an understanding of our financial condition, changes in financial condition and results of our operations. The discussion and analysis presented below refer to and should be read in conjunction with the unaudited interim consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the year ended December 31, 2016.

Unless the context otherwise requires, references herein to “The Chemours Company”, “Chemours”, “the Company”, “our company”, “we”, “us” and “our” refer to The Chemours Company and its consolidated subsidiaries. References herein to “DuPont” refer to E.I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries (other than Chemours and its consolidated subsidiaries), unless the context otherwise requires.

### Forward-Looking Statements

This section and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words “believe”, “expect”, “anticipate”, “plan”, “estimate”, “target”, “project” and similar expressions, among others, generally identify “forward-looking statements”, which speak only as of the date the statements were made.

Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Chemours’ control. Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those set forth in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in the Forward-Looking Statements and the Risk Factors sections in our Annual Report on Form 10-K for the year ended December 31, 2016. The Company assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

### Overview

Chemours is a leading global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial and mining. Principal products include titanium dioxide (TiO2), refrigerants, industrial fluoropolymer resins, sodium cyanide and performance chemicals and intermediates.

Chemours manages and reports operating results through three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. Our position with each of these businesses reflects the strong value proposition we provide to our customers based on our long history and reputation in the chemical industry for safety, quality and reliability.

#### Transformation Plan

After the separation from DuPont in 2015, Chemours announced a plan to transform the Company by reducing structural costs, growing market positions, optimizing its portfolio, refocusing investments and enhancing its organization. Chemours expects the transformation plan to deliver $500 million of incremental adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) improvement over 2015 through 2017 based on our anticipated cost reduction and growth initiatives. We expect cost savings of approximately $350 million and approximately $150 million in improvements from growth initiatives will also improve our pre-tax earnings by similar amounts. Through year-end 2016, we realized approximately $200 million in cost savings, and we continue to implement additional cost reduction initiatives in order to realize our target additional structural costs savings of approximately $150 million through 2018. These improvements will be partially offset by the impact of divestitures completed during 2016, unfavorable price and mix of other products and may also be impacted by market factors and other costs to achieve our plans. Results of our transformation actions are further discussed in the Results of Operations, Segment Reviews and Outlook sections of this MD&A and in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

### Recent Developments

In May 2017, we completed an offering (Offering) of $500 million aggregate principal amount of 5.375% Senior Unsecured Notes due 2027. We will use the net proceeds of the Offering for general corporate purposes, including our portion of the global settlement of the PFOA MDL Settlement litigation between DuPont and the plaintiffs, which is expected to be paid in August 2017. Details of the Offering are discussed further in the Credit Facilities and Notes section within Liquidity and Capital Resources of this MD&A. Details of the PFOA MDL Settlement are discussed further in Note 13 to the Interim Consolidated Financial Statements in Item 1.

In April 2017, we completed the sale of our corporate headquarters building located in Wilmington, Delaware for net proceeds of $29 million. We used $13 million of the net proceeds from this sale to repay a portion of our outstanding term loans in accordance with the credit agreement, as amended. Also, in connection with the sale, we entered into lease agreements to lease back a portion of the building beginning in April 2017. In connection with the sale and leaseback transaction, we deferred a gain of $2 million.

Also, in April 2017, we entered into an amendment to our existing credit agreement to provide a new class of term loans denominated in Euros and U.S. Dollars, in an aggregate principal amount of €400 million and $940 million, respectively. The proceeds from the new class of term loans were used to repay in full the existing senior secured term loan outstanding of approximately $1.4 billion. No incremental debt was issued as a result of the amendment. Details of the amendment are discussed further in the Credit Facilities and Notes section within Liquidity and Capital Resources of this MD&A.

### Our Second Quarter 2017 Results and Business Highlights

Net sales for the three months ended June 30, 2017 were $1.6 billion, representing an increase of 15% from $1.4 billion for the three months ended June 30, 2016. Net sales for the six months ended June 30, 2017 were $3.0 billion, representing an increase of 13% from $2.7 billion for the six months ended June 30, 2016.

We recognized net income attributable to Chemours of $161 million and $311 million for the three and six months ended June 30, 2017, respectively. We recognized a net loss attributable to Chemours of $18 million and net income attributable to Chemours of $33 million for the three and six months ended June 30, 2016, respectively.

Our Adjusted EBITDA was $361 million and $647 million for the three and six months ended June 30, 2017, respectively, compared with $187 million and $315 million for the three and six months ended June 30, 2016, respectively. Our results for the periods presented reflect increased pricing and volume in our Titanium Technologies segment, increased volume for Opteon™ and other fluoropolymers products in our Fluoroproducts segment and increased volume in our Chemical Solutions segment. Increases in pricing and volume across the segments were partially offset by the impact of portfolio changes in our Chemical Solutions segment as well as higher costs for transformation activities and performance-related compensation.

### Results of Operations

*(Dollars in millions)*

|  | Three Months Ended June 30, 2017 | 2016 | Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,588 | $1,383 | $3,024 | $2,680 |
| Cost of goods sold | 1,147 | 1,116 | 2,225 | 2,212 |
| Gross profit | 441 | 267 | 799 | 468 |
| Selling, general and administrative expense | 157 | 174 | 301 | 307 |
| Research and development expense | 21 | 17 | 40 | 40 |
| Restructuring and asset-related charges, net | 6 | 67 | 18 | 85 |
| Total expenses | 184 | 258 | 359 | 432 |
| Equity in earnings of affiliates | 10 | 4 | 17 | 9 |
| Interest expense, net | (55) | (50) | (106) | (106) |
| Other income (expense), net | 13 | (4) | 48 | 89 |
| **Income (loss) before income taxes** | 225 | (41) | 399 | 28 |
| Provision for (benefit from) income taxes | 64 | (23) | 87 | (5) |
| **Net income (loss)** | 161 | (18) | 312 | 33 |
| Less: Net income attributable to non-controlling interests | — | — | 1 | — |
| **Net income (loss) attributable to Chemours** | $161 | $(18) | $311 | $33 |

31

### Net Sales

Net sales for the three months ended June 30, 2017 were $1.6 billion, representing an increase of 15% from $1.4 billion for the three months ended June 30, 2016. Net sales for the six months ended June 30, 2017 were $3.0 billion, representing an increase of 13% from $2.7 billion for the six months ended June 30, 2016.

The increase in net sales for the three months ended June 30, 2017 reflects increased pricing in our Titanium Technologies segment of approximately 7%, as well as increases in volume across all three of our segments of approximately 15%. These increases were partially offset by the impact of portfolio changes in our Chemical Solutions segment of 6% and foreign currency exchange rate changes of 1%. The increase in net sales for the six months ended June 30, 2017 reflects increased pricing in our Titanium Technologies segment of approximately 6%, as well as increases in volume across all three of our segments of approximately 14%. These increases were partially offset by the impact of portfolio changes in our Chemical Solutions segment of 7%.

The following table shows the impact of price, volume, currency and portfolio changes on net sales for the three and six months ended June 30, 2017 compared with the three and six months ended June 30, 2016:

| Change in net sales from prior period | Three Months Ended June 30, 2017 | Six Months Ended June 30, 2017 |
| --- | ---: | ---: |
| Price | 7% | 6% |
| Volume | 15% | 14% |
| Currency | (1)% | —% |
| Portfolio / other | (6)% | (7)% |
| Total change | 15% | 13% |

For a detailed discussion of net sales, see the Segment Reviews section of this MD&A.

### Cost of goods sold

Cost of goods sold (COGS) increased by $31 million, or 3%, and $13 million, or 1%, for the three and six months ended June 30, 2017, respectively, when compared with the same periods in 2016. The increase in COGS during the three and six months ended June 30, 2017 was primarily driven by increases in volume, as well as costs associated with transformation activities. Additionally, performance-related compensation increased COGS by approximately $10 million during the three and six months ended June 30, 2017 when compared with the same periods in 2016. These increases were partially offset by the impact of portfolio changes in our Chemical Solutions segment.

### Selling, general and administrative expense

Selling, general and administrative (SG&A) expense decreased by $17 million, or 10%, to $157 million for the three months ended June 30, 2017 when compared with $174 million for the three months ended June 30, 2016. The decrease in SG&A expense was primarily attributable to a reduction in management and administrative expense, as well as timing of legal fees. Further, during the three months ended June 30, 2016, we incurred $12 million of pre-sale transaction costs associated with the sale of our Sulfur and Clean & Disinfectant (C&D) businesses, which did not recur in 2017. These decreases were partially offset by additional charges of $19 million related to transformation activities.

SG&A expense decreased by $6 million, or 2%, to $301 million for the six months ended June 30, 2017 when compared with $307 million for the six months ended June 30, 2016. The decrease in SG&A expense for the six months ended June 30, 2017 was primarily attributable to a reduction in management and administrative expense. Further, during the six months ended June 30, 2016, we incurred $15 million of pre-sale transaction costs associated with the sale of our Sulfur and C&D businesses, which did not recur in 2017. These decreases were partially offset by additional charges of $27 million for transformation activities and $6 million of additional performance-related compensation accruals during the six months ended June 30, 2017.

### Research and development expense

Research and development (R&D) expense increased by $4 million, or 24%, to $21 million for the three months ended June 30, 2017 when compared with $17 million for the three months ended June 30, 2016. R&D expense for the six months ended June 30, 2017 and 2016 remained constant at $40 million. The increase in R&D expense for the three months ended June 30, 2017 was driven primarily by performance-related compensation during the period.

### Restructuring and asset-related charges, net

During the three and six months ended June 30, 2017, we recorded pre-tax charges of $6 million and $18 million for restructuring and asset-related charges, net, respectively, compared with $67 million and $85 million for the three and six months ended June 30, 2016, respectively. Our 2017 charges primarily represent decommissioning and other charges associated with the production shutdown at our Reactive Metals Solutions (RMS) facility in Niagara Falls, New York.

Charges for the three months ended June 30, 2016 consist primarily of $9 million related to our Edge Moor, Delaware manufacturing plant decommission and dismantling activities and a $58 million pre-tax impairment loss associated with the sale of our Sulfur business. Charges for the six months ended June 30, 2016 consist primarily of $18 million related to our Edge Moor manufacturing plant decommission and dismantling activities, $7 million related to decommissioning activities of certain product lines in our Fluoroproducts segment and a $58 million pre-tax impairment loss associated with the sale of our Sulfur business.

For details related to restructuring and asset-related charges, net, see Note 3 to the Interim Consolidated Financial Statements in Item 1.

### Interest expense, net

We incurred interest expense of $55 million and $106 million for the three and six months ended June 30, 2017, respectively, compared with $50 million and $106 million for the three and six months ended June 30, 2016, respectively.

Interest expense increased by approximately $5 million for the three months ended June 30, 2017 primarily due to the issuance of the May 2027 Notes.

### Other income (expense), net

We recognized other income of $13 million and $48 million for the three and six months ended June 30, 2017, respectively, compared with other expense of $4 million and other income of $89 million for the three and six months ended June 30, 2016, respectively. The increase for the three months ended June 30, 2017 was primarily driven by a $2 million foreign exchange gain during the quarter, compared to a $14 million loss for the three months ended June 30, 2016. The decrease for the six months ended June 30, 2017 was primarily due to an $89 million gain from the sale of our aniline facility in Beaumont, Texas to the Dow Chemical Company in the first quarter of 2016, which did not recur in 2017. The decrease for the six months ended June 30, 2017 was partially offset by a $7 million foreign exchange gain during the quarter compared to a $20 million loss for the three months ended June 30, 2016.

For additional details on other income (expense), net and foreign currency forward contracts, see Note 4 and Note 14 to the Interim Consolidated Financial Statements in Item 1, respectively.

### Provision for income taxes

For the three months ended June 30, 2017 and 2016, Chemours recorded a provision for income tax of $64 million and an income tax benefit of $23 million, respectively, resulting in an effective income tax rate of 28% and 56%, respectively. For the six months ended June 30, 2017 and 2016, Chemours recorded a provision for income tax of $87 million and an income tax benefit of $5 million, respectively, resulting in an effective tax rate of 22% and negative 18%, respectively.

The income tax provision for the three and six months ended June 30, 2017 is inclusive of a $3 million and $13 million income tax benefit from windfalls on share-based payments, respectively, due to our adoption of ASU No. 2016-09 during 2017. The remaining change in the effective tax rate from the prior year is primarily due to the Company’s geographical mix of earnings as well as the impact of the additional valuation allowance on U.S. foreign tax credits of approximately $9 million and $14 million for the three and six months ended June 30, 2017, respectively, from which the Company does not expect to benefit from in the current year.

### Segment Reviews

The following table represents Chemours’ total consolidated Adjusted EBITDA by segment:

*(Dollars in millions)*

|  | Three Months Ended June 30, 2017 | 2016 | Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| Titanium Technologies | $193 | $111 | $352 | $166 |
| Fluoroproducts | 197 | 105 | 352 | 190 |
| Chemical Solutions | 7 | 11 | 19 | 21 |
| Corporate and Other | (36) | (40) | (76) | (62) |
| Total | $361 | $187 | $647 | $315 |

33

Corporate costs and certain legal and environmental expenses that are not allocated to the segments are reflected in Corporate and Other. The decrease of $4 million in Corporate and Other costs for the three months ended June 30, 2017 when compared with the same period in 2016 reflects timing of legal costs. The increase of $14 million in Corporate and Other costs for the six months ended June 30, 2017 when compared with the same period in 2016 relates to higher performance-related compensation expense and higher first quarter legal costs.

Adjusted EBITDA represents our primary measure of segment performance and is defined as income (loss) before income taxes excluding the following:

- interest expense, depreciation and amortization;
- non-operating pension and other post-retirement employee benefit costs, which represent the component of net periodic pension (income) costs excluding service cost component;
- exchange (gains) losses included in other income (expense), net of the consolidated statement of operations;
- restructuring, asset-related charges and other charges, net;
- asset impairments;
- (gains) losses on sale of business or assets; and
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

A reconciliation of Adjusted EBITDA to net income (loss) attributable to Chemours for the three and six months ended June 30, 2017 and 2016 is included in the Non-GAAP Financial Measures in this Item 2 and in Note 17 to the Interim Consolidated Financial Statements in Item 1.

### Titanium Technologies

*(Dollars in millions)*

|  | Three Months Ended June 30, 2017 | 2016 | Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| Segment net sales | $729 | $596 | $1,375 | $1,117 |
| Adjusted EBITDA | 193 | 111 | 352 | 166 |
| Adjusted EBITDA margin | 26% | 19% | 26% | 15% |

| Change in segment net sales from prior period | Three Months Ended June 30, 2017 | Six Months Ended June 30, 2017 |
| --- | ---: | ---: |
| Price | 15% | 15% |
| Volume | 8% | 9% |
| Currency | (1)% | (1)% |
| Portfolio / other | —% | —% |
| Total change | 22% | 23% |

***Segment Net Sales:*** Net sales increased by 22% and 23% for the three and six months ended June 30, 2017, respectively, when compared with the same periods in 2016. For the three months ended June 30, 2017, 15% of the increase in net sales was primarily attributable to improved price and 8% of the increase was attributable to higher demand. For the six months ended June 30, 2017, 15% of the increase in net sales was primarily attributable to improved price and 9% of the increase was attributable to higher demand. These increases were slightly offset by unfavorable foreign currency impacts for the three and six months ended June 30, 2017.

***Adjusted EBITDA and Adjusted EBITDA Margin:*** Adjusted EBITDA increased by 74% and 112% for the three and six months ended June 30, 2017, respectively, when compared with the same periods in 2016. Our Adjusted EBITDA margin increased by 7% and 11% for the three and six months ended June 30, 2017, respectively, when compared with the same periods in 2016. The increases in Adjusted EBITDA and Adjusted EBITDA margin were primarily attributable to the aforementioned increases in price and volume. The increases were partially offset by higher costs primarily related to transformation activities and performance-related compensation.

### Fluoroproducts

*(Dollars in millions)*

|  | Three Months Ended June 30, 2017 | 2016 | Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| Segment net sales | $710 | $573 | $1,360 | $1,104 |
| Adjusted EBITDA | 197 | 105 | 352 | 190 |
| Adjusted EBITDA margin | 28% | 18% | 26% | 17% |

| Change in segment net sales from prior period | Three Months Ended June 30, 2017 | Six Months Ended June 30, 2017 |
| --- | ---: | ---: |
| Price | 1% | —% |
| Volume | 23% | 23% |
| Currency | —% | —% |
| Portfolio / other | —% | —% |
| Total change | 24% | 23% |

***Segment Net Sales:*** Net sales increased by 24% and 23% for the three and six months ended June 30, 2017, respectively, when compared with the same periods in 2016. The increase in net sales for the three and six months ended June 30, 2017 was primarily attributable to continuing solid demand for Opteon™ refrigerant in the U.S. and Europe as well as increases in demand for our fluoropolymer products, leading to volume increases of 23% over the same periods in 2016. Additionally, price increases improved net sales by 1% for the three months ended June 30, 2017 when compared with the same period in 2016.

***Adjusted EBITDA and Adjusted EBITDA Margin:*** Adjusted EBITDA increased by 88% and 85% for the three and six months ended June 30, 2017, respectively, when compared with the same periods in 2016. Our Adjusted EBITDA margin increased by 10% and 9% for the three and six months ended June 30, 2017, respectively, when compared with the same periods in 2016. The increases in Adjusted EBITDA and Adjusted EBITDA margin were primarily attributable to the aforementioned volume increases, which were partially offset by higher costs related to transformation activities and performance-related compensation.

### Chemical Solutions

*(Dollars in millions)*

|  | Three Months Ended June 30, 2017 | 2016 | Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| Segment net sales | $149 | $214 | $289 | $459 |
| Adjusted EBITDA | 7 | 11 | 19 | 21 |
| Adjusted EBITDA margin | 5% | 5% | 7% | 5% |

| Change in segment net sales from prior period | Three Months Ended June 30, 2017 | Six Months Ended June 30, 2017 |
| --- | ---: | ---: |
| Price | 1% | 1% |
| Volume | 9% | 5% |
| Currency | —% | —% |
| Portfolio / other | (40)% | (43)% |
| Total change | (30)% | (37)% |

***Segment Net Sales:*** Net sales decreased by 30% and 37% for the three and six months ended June 30, 2017, respectively, when compared with the same periods in 2016. The decrease in net sales for the three and six months ended June 30, 2017 was primarily attributable to portfolio changes resulting from the sale of our aniline facility in Beaumont and our C&D and Sulfur businesses, as well as the production shutdown at our RMS facility in Niagara Falls, which collectively represented a decrease in net sales of 40% and 43% when compared with the three and six months ended June 30, 2016, respectively. The decrease in net sales was offset by volume increases of 9% and 5% and modest price increases in the remaining segment for the three and six months ended June 30, 2017, respectively.

***Adjusted EBITDA and Adjusted EBITDA Margin:*** Adjusted EBITDA decreased by 36% and 10% for the three and six months ended June 30, 2017, respectively, when compared with the same periods in 2016. Our Adjusted EBITDA margin remained consistent at 5% for the three months ended June 30, 2017 and 2016 and increased by 2% for the six months ended June 30, 2017 when compared with the six months ended June 30, 2016. The changes in Adjusted EBITDA and Adjusted EBITDA margin are primarily attributable to portfolio changes and other cost reduction initiatives, including the production shutdown at our RMS facility in Niagara Falls.

### 2017 Outlook

For the remainder of the year, we continue to anticipate that the Company’s revenue and earnings performance will remain strong. We expect to deliver full-year Adjusted EBITDA improvement, with similar pre-tax income improvement, substantially in line with our transformation goals. We are committed to delivering additional structural cost savings of approximately $150 million and we continue to implement certain initiatives in order to realize our target cost savings, which are expected to be fully realized in 2018. We also expect to generate breakeven free cash flow for the full-year 2017, including payments relating to the PFOA MDL Settlement. Our outlook reflects our current visibility and expectations on market factors, such as currency movements, TiO2 pricing, end-market demand and seasonality.

### Liquidity and Capital Resources

Chemours’ primary source of liquidity is cash generated from operations, available cash and borrowings under debt financing arrangements. We believe these sources are sufficient to fund our planned operations and to meet our interest, dividend and contractual obligations. Our financial policy seeks to selectively invest for growth to enhance our portfolio including certain strategic capital investments, return cash to shareholders through dividend payments and possible share repurchases in the future and maintain appropriate leverage by using free cash flow to repay outstanding borrowings. Subject to approval, we may raise additional capital or borrowings from time to time. However, there can be no assurance that future capital or borrowings will be available to us, and the cost and availability of new capital or borrowings could be materiality impacted by market conditions.

Over the next 12 months, Chemours expects to have significant interest, capital expenditures, PFOA MDL Settlement, restructuring and dividend payments. We expect to fund these payments through cash generated from operations, available cash and borrowings. We anticipate that our operations and existing debt financing arrangements will provide sufficient liquidity over the next 12 months. Availability under our Revolving Credit Facility, which is discussed further in the Credit Facilities and Notes section of this MD&A, is subject to the last 12 months of our consolidated EBITDA, as defined under the credit agreement.

As of June 30, 2017 and December 31, 2016, we had $805 million and $678 million, respectively, of cash and cash equivalents on our consolidated balance sheets held by our foreign subsidiaries, all of which is readily convertible into currencies used in our operations, including the U.S. Dollar. Cash and earnings of our foreign subsidiaries are generally used to finance their operations and capital expenditures. At June 30, 2017 and December 31, 2016, management believed that sufficient liquidity was available in the U.S., and it is our intention to indefinitely reinvest undistributed earnings of our foreign subsidiaries outside of the U.S. No deferred tax liabilities have been recognized with regard to the $805 million and $678 million of cash and cash equivalents held by our foreign subsidiaries as of June 30, 2017 and December 31, 2016, respectively, as well as our undistributed earnings. The potential tax implications of the repatriation of unremitted earnings are driven by facts at the time of distribution. Therefore, it is not practicable to estimate the income tax liabilities that might be incurred if such cash and earnings were repatriated to the U.S.

### Cash Flows

The following table sets forth a summary of the net cash provided by (used for) operating, investing and financing activities:

*(Dollars in millions)*

|  | Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: |
| Cash provided by operating activities | $224 | $126 |
| Cash used for investing activities | (98) | (18) |
| Cash provided by (used for) financing activities | 483 | (108) |

#### Operating Activities

Cash provided by operating activities increased by $98 million for the six months ended June 30, 2017 when compared with the same period in 2016. Excluding the advance payment of $190 million from Dupont, total cash provided by operating activities improved by $229 million, primarily due to favorable increases in our operating results for the six months ended June 30, 2017 when compared with the same period in 2016. As of June 30, 2017, all of the advance payment from DuPont had been utilized.

#### Investing Activities

Cash used for investing activities increased by $80 million for the six months ended June 30, 2017 when compared with the same period in 2016. Cash used for investing activities for the six months ended June 30, 2017 primarily related to capital expenditures of

$138 million during the period, offset by net proceeds received from the sale of our corporate headquarters building in Wilmington for $29 million and the sale of our manufacturing plant in Edge Moor for $9 million. Cash used for investing activities for the six months ended June 30, 2016 primarily related to capital expenditures of $168 million during the period, offset by net proceeds from the sale of our aniline facility in Beaumont for $140 million. Our capital expenditures for the six months ended June 30, 2017 decreased by $30 million when compared with the same period in 2016, primarily due to lower spending with the completion of our Altamira, Mexico plant expansion in April 2016.

We expect our full year capital expenditures in 2017 to be between $400 million and $450 million, which exceeds our annual capital expenditures in 2016, primarily due to expenditures associated with our new OpteonTM plant under construction in Corpus Christi, Texas and our Mining Solutions expansion, which began in June 2017.

#### Financing Activities

Cash provided by financing activities was $483 million for the six months ended June 30, 2017. In May 2017, we issued a $500 million aggregate principal amount of 5.375% senior unsecured notes due May 2027. Net proceeds from this issuance amounted to $489 million, which is net of an issue discount of $5 million and underwriting fees and other related expenses of $6 million.

During the six months ended June 30, 2017, consistent with the same period in 2016, we made the quarterly required repayments on our senior secured term loans equivalent to 1% per annum of the original principal, which amounted to $7 million. In addition, we used $13 million of the net proceeds received from the sale of our corporate headquarters building in Wilmington to repay a portion of the senior secured term loans. Further, we declared and paid approximately $11 million of dividends to our shareholders, which was equivalent to $0.06 per share. These cash payments were offset by cash receipts of $26 million for stock options exercised during the first half of 2017. No similar stock options were exercised through the first half of 2016.

### Current Assets

*(Dollars in millions)*

|  | June 30, 2017 | December 31, 2016 |
| --- | ---: | ---: |
| Cash and cash equivalents | $1,529 | $902 |
| Accounts and notes receivable - trade, net | 994 | 807 |
| Inventories | 848 | 767 |
| Prepaid expenses and other | 69 | 77 |
| Total current assets | $3,440 | $2,553 |

Accounts and notes receivable - trade, net at June 30, 2017 increased by $187 million compared with December 31, 2016 primarily due to higher sales in the second quarter of 2017 over the fourth quarter of 2016 and favorable currency translation impact of approximately $15 million.

Inventories at June 30, 2017 increased by $81 million compared with December 31, 2016 due to inventory build for increasing sales demand, primarily in the Titanium Technologies segment, and favorable currency translation impact of approximately $16 million.

### Current Liabilities

*(Dollars in millions)*

|  | June 30, 2017 | December 31, 2016 |
| --- | ---: | ---: |
| Accounts payable | $985 | $884 |
| Current maturities of long-term debt | 14 | 15 |
| Other accrued liabilities | 751 | 872 |
| Total current liabilities | $1,750 | $1,771 |

As of June 30, 2017, accounts payable increased by $101 million compared with December 31, 2016 due to higher inventories and timing of payments to vendors.

Other accrued liabilities decreased by $121 million compared with December 31, 2016 due to utilization of the DuPont prepayment of approximately $58 million, severance payments of approximately $21 million, payment of the PFOA MDL Settlement in May 2017 for $15 million and payment of performance-related compensation in March 2017.

### Credit Facilities and Notes

Our credit agreement, as amended, includes a seven-year senior secured term loan and a five-year $750 million senior secured revolving credit facility (Revolving Credit Facility). The proceeds of loans made under the Revolving Credit Facility can be used to finance capital expenditures, acquisitions, working capital needs and for other general corporate purposes. Availability under the Revolving Credit Facility is subject to certain covenant limitations. At June 30, 2017, the facility had a full borrowing capacity of $750 million, from which we had $104 million of letters of credit issued and outstanding under this facility.

On April 3, 2017, we completed an amendment (April 2017 Amendment) to our credit agreement which provides for a new class of term loans, denominated in Euros, in an aggregate principal amount of €400 million (Euro Term Loan), and a new class of term loans, denominated in U.S. Dollars, in an aggregate principal amount of $940 million (Dollar Term Loan, and, collectively with the Euro Term Loan, the New Term Loans). The New Term Loans replaced in full the existing term loan (Prior Term Loan) outstanding of approximately $1.4 billion. The New Term Loans mature on May 12, 2022, which is the same maturity date of the Prior Term Loan. The Euro Term Loan bears a variable interest rate equal to EURIBOR plus 2.25%, subject to a EURIBOR floor of 0.75%, and the Dollar Term Loan bears a variable interest rate equal to LIBOR plus 2.50%, subject to a LIBOR floor of 0.00%. The April 2017 Amendment also modifies certain provisions of the credit agreement, including increasing certain incurrence limits to allow further flexibility for the Company. All other provisions, including financial covenants, remain unchanged. No incremental debt was issued as a result of the April 2017 Amendment, although the Euro Term Loan will be subject to remeasurement gains or losses. We recorded approximately $3 million of loss on debt extinguishment and related amendment fees in the second quarter of 2017.

The credit agreement, as amended, contains financial covenants which, solely with respect to the Revolving Credit Facility, require us not to exceed a maximum senior secured net leverage ratio of: 3.50 to 1.00 each quarter through December 31, 2016; 3.00 to 1.00 through June 30, 2017; and further decreasing by 0.25 to 1.00 every subsequent six months to 2.00 to 1.00 by January 1, 2019 and thereafter. We are also required to maintain a minimum interest coverage ratio of 1.75 to 1.00 each quarter through June 30, 2017 and further increasing by 0.25 to 1.00 every subsequent six months to 3.00 to 1.00 by January 1, 2019 and thereafter. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict us and our subsidiaries’ ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default. The senior secured credit facilities and the Notes (collectively, the 2023 Notes, the 2025 Notes, the Euro Notes and the 2027 Notes) contain events of default customary for these types of financings, including cross default and cross acceleration provisions to material indebtedness of Chemours. We were in compliance with our debt covenants as of June 30, 2017.

In the event of default under the Revolving Credit Facility, our lenders under the Revolving Credit Facility can terminate their commitments thereunder, cease making further revolving loans and accelerate outstanding revolving loans. This would allow the lenders under the Revolving Credit Facility to declare the outstanding term loans to be immediately due and payable and to institute foreclosure proceedings against the collateral securing the credit facility, which could force us into bankruptcy or liquidation. Any event of default or declaration of acceleration under the credit agreement also may result in an event of default under the indentures governing the Notes. Any such default, event of default or declaration of acceleration could materially and adversely affect our results of operations and financial condition. Please see the section titled Risks Related to Our Indebtedness of the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2016 for additional detail.

For the remainder of 2017, under the April 2017 Amendment, we are required to make principal payments related to the New Term Loans of approximately $7 million and approximately $14 million in each year from 2018 to 2021. Debt maturities related to the New Term Loans and the Notes in 2022 and beyond will be $4,060 million. In addition, following the end of each fiscal year commencing on the year ended December 31, 2016, on an annual basis, we are also required to make additional principal repayments, depending on our leverage level as defined in the credit agreement, equivalent to up to 50% of excess cash flow based on certain leverage targets with stepdowns to 25% and 0% as actual leverage decreases to below the 3.00 to 1.00 leverage target at the end of each fiscal year. No principal repayments were required to be made in 2017 based upon the December 31, 2016 excess cash flow determined under the credit agreement. See Note 12 to the Interim Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information related to our indebtedness.

On May 23, 2017, Chemours issued a $500 million aggregate principal amount of 5.375% senior unsecured notes due May 2027 (2027 Notes). The 2027 Notes require payment of principal at maturity and interest semi-annually in cash and in arrears on May 15 and November 15 of each year. The Company received net proceeds of approximately $489 million, net of issue discount of approximately $5 million and underwriting fees and other related expenses of approximately $6 million, which are deferred and amortized to interest expense using the effective interest method over the term of the 2027 Notes. The proceeds from the 2027 Notes will be used for general corporate purposes, including the previously announced PFOA MDL Settlement, if finalized.

The 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis by each of the existing and future domestic subsidiaries that (a) incurs or guarantees indebtedness under the Senior Secured Credit Facilities or

(b) guarantees other indebtedness of Chemours or any guarantor in an aggregate principal amount in excess of $100 million. The guarantees of the 2027 Notes will rank equally with all other senior indebtedness of the guarantors. The 2027 Notes rank equally in right of payment to all of Chemours’ existing and future unsecured unsubordinated debt and senior in right of payment to all of Chemours’ existing and future debt that is by its terms expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes are subordinated to indebtedness under the Senior Secured Credit Facilities as well as any future secured debt to the extent of the value of the assets securing such debt, and structurally subordinated to the liabilities of any non-guarantor subsidiaries.

Chemours may redeem the 2027 Notes, in whole or in part, equal to 100% of the aggregate principal amount plus a specified “make-whole” premium and accrued and unpaid interest, if any, to the date of purchase prior to February 15, 2027 and may also redeem some or all of the 2027 Notes by means other than a redemption, including tender offer and open market repurchases. Chemours is obligated to offer to purchase the 2027 Notes at a price of 101% of the principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase, upon the occurrence of certain change of control events.

### Supplier Financing

In 2015, we entered into a global paying services agreement with a financial institution. Under this agreement, the financial institution acts as the paying agent for Chemours with respect to accounts payable due to our suppliers who elect to participate in the program. The agreement allows our suppliers to sell their receivables to the financial institution at the discretion of both parties on terms that are negotiated between them. Our obligations to our suppliers, including the amounts due and scheduled payment dates, are not impacted by our suppliers’ decisions to sell their receivables under this program. At June 30, 2017, the payment instructions from Chemours were $175 million. Pursuant to their agreement with the financial institution, certain suppliers may elect to get paid early at their discretion. The available capacity under this program can vary based on the number of investors participating in this program at any point in time.

### Contractual Obligations

During the quarter ended June 30, 2017, the Company completed the April 2017 Amendment to its credit agreement, providing for the Euro Term Loan, a new class of term loans, denominated in Euros, in an aggregate principal amount of €400 million and the Dollar Term Loan, a new class of term loans, denominated in U.S. Dollars, in an aggregate principal amount of $940 million. The New Term Loans replaced in full the Prior Term Loan outstanding of approximately $1.4 billion, and no incremental debt was incurred as a result of the April 2017 Amendment. Also, in May 2017, the Company issued the 2027 Notes, a $500 million aggregate principal amount of 5.375% senior unsecured notes due May 2027. Both transactions are further described in the Credit Facilities and Notes section of this MD&A.

Due to the updated terms of these financing arrangements, information related to the Company’s total debt-related contractual obligations is shown below. Interest rates and foreign exchange rates reflect the prevailing rates as of June 30, 2017.

*(Dollars in millions)*

|  | Total at June 30, 2017 | Payments Due In Remainder of 2017 | 2018 - 2019 | 2020 - 2021 | 2022 and Beyond |
| --- | ---: | ---: | ---: | ---: | ---: |
| Long-term debt obligations | $4,123 | $7 | $29 | $27 | $4,060 |
| Interest payments on long-term debt obligations | 1,493 | 109 | 445 | 443 | 496 |

### Off Balance Sheet Arrangements

Information with respect to Chemours’ guarantees is included Note 20 to the Consolidated Financial Statements in the Annual Report on Form 10-K for the year ended December 31, 2016. Historically, Chemours has not made significant payments to satisfy guarantee obligations; however, Chemours believes it has the financial resources to satisfy these guarantees in the event required. Remaining guarantees outstanding as of June 30, 2017 were insignificant.

### Critical Accounting Policies and Estimates

Chemours’ significant accounting policies are described in Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Estimates and Note 3 to the Consolidated Financial Statements in our Annual Report on Form 10-K. There have been no material changes to our critical accounting policies and estimates previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016.

### Recent Accounting Pronouncements

See Note 2 to the Interim Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for discussions of recent accounting pronouncements.

### Environmental Matters

Consistent with our Chemours values and our Environment, Health and Safety Policy, Chemours is committed to preventing releases to the environment at our manufacturing sites to keep our people and communities safe and to be good stewards of the environment. Chemours is also subject to environmental laws and regulations relating to the protection of the environment. We believe that, as a general matter, our policies, standards and procedures are properly designed to prevent unreasonable risk of harm to people and the environment, and that our handling, manufacture, use and disposal of hazardous substances are in accordance with applicable environmental laws and regulations.

### Environmental Remediation

Mainly because of past operations, operations of predecessor companies or past disposal practices, we, like many other similar companies, have clean-up responsibilities, associated remediation costs and are subject to claims by other parties, including claims for matters that are liabilities of DuPont and its subsidiaries that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the separation.

Our environmental reserve includes estimated costs related to a number of sites for which it is probable that environmental remediation will be required, whether or not subject to enforcement activities, as well as those obligations that result from environmental laws such as the Comprehensive Environmental Response Compensation and Liability Act (CERCLA, often referred to as Superfund), the Resource Conservation and Recovery Act (RCRA) and similar state, federal and foreign laws. These laws require certain investigative, remediation and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. At June 30, 2017 and December 31, 2016, we recorded environmental remediation accruals of $278 million, which, in management’s opinion, is appropriate based on existing facts and circumstances.

Our remediation portfolio is relatively mature, with many of our sites under active clean-up moving towards final completion. As remediation efforts progress, sites move from the investigation phase to the active clean-up phase, and as construction is completed at active clean-ups, those sites move to the ongoing maintenance and monitoring (OM&M) or closure phase. As final clean-ups for some significant sites are completed over the next several years, we expect our annual expenses related to these active sites to decline over time. The time-frame for a site to go through all phases of remediation (investigation and active clean-up) may take about 15 to 20 years, followed by several years of OM&M activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties. In addition, for claims that Chemours may be required to indemnify DuPont pursuant to the separation-related agreements, Chemours, through DuPont, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, although deemed remote, the potential liability may range up to approximately $480 million above the amount accrued at June 30, 2017. In general, uncertainty is greatest and the range of potential liability is widest in the investigation phase, and narrows over time as regulatory agencies approve site remedial plans, uncertainty is reduced and, ultimately, sites move into OM&M, where needed. As more sites advance from investigation to active clean-up to OM&M or closure, the upper end of the range of potential liability is expected to decrease over time.

Some remediation sites will achieve site closure and will require no further action to protect people and the environment and comply with laws and regulations. At certain sites, we expect that there will continue to be some level of remediation activity due to ongoing monitoring and/or operations and maintenance of remedial systems. In addition, portfolio changes such as an acquisition or divestiture or notification as a potentially responsible party for a multi-party Superfund site could result in additional remediation activity and potentially additional accrual.

Management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on our financial position, results of operations or cash flows in any given year, as such obligation can be satisfied or settled over many years. For additional information, refer to the Environmental Matters section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2016.

While there are many remediation sites that contribute to the total environmental remediation accrual, the following sites are among the most significant:

*(Dollars in millions)*

|  | June 30, 2017 | December 31, 2016 |
| --- | ---: | ---: |
| Beaumont, Texas | $12 | $12 |
| Chambers Works, New Jersey | 24 | 24 |
| East Chicago, Indiana | 20 | 20 |
| Pompton Lakes, New Jersey | 75 | 77 |
| USS Lead, East Chicago, Indiana | 24 | 21 |
| All other sites | 123 | 124 |
| Total reserve | $278 | $278 |

The five sites listed above represent more than 50% of our reserve and we expect to spend, in aggregate, approximately $108 million over the next three years. For all other sites, we expect to spend approximately $79 million over the next three years.

#### Beaumont Works, Beaumont, Texas

Beaumont Works began operations in 1954 in Beaumont, Jefferson County, Texas. Over the years, Beaumont Works has produced a number of basic chemicals and elastomer products including acrylonitrile, ammonia, methanol, methyl methacrylate, caprolactam, Hypalon® synthetic rubber, Nordel® hydrocarbon rubber and blended tetraethyl lead with halo-carbon solvent/stabilizers. As of June 30, 2017, with sale of the aniline production unit to Dow in 2016, Chemours has no ongoing manufacturing operations on the site. Dow and Lucite remain as long-term manufacturing tenants.

As site owner, Chemours remains responsible for remediation of historical chemical releases from past operations and is conducting this work under a RCRA hazardous waste post-closure permit and Compliance Plan (CP) issued by the State of Texas. The hazardous waste permit includes provisions to manage wastes and to investigate and mitigate releases. The CP is a component of the permit and includes mitigation and monitoring requirements, including a groundwater remediation system that was installed in 1991 to control chemical migration and protect adjacent water bodies. In addition, several solid waste management unit closures have been conducted and areas of past release addressed through interim measures to protect people and the environment. Over the years, extensive site studies have been completed and a final investigation report (Affected Property Assessment Report, or APAR, under the Texas Risk Reduction Program) for the entire site was approved by the state in 2014. Chemours has recently completed a remedial action plan (RAP), currently under agency review, to address all remaining historical solid waste management units and areas of concern identified in these studies, and expects to have this RAP approved in 2017.

The remediation accrual for Beaumont addresses remaining work identified in the RAP under review by the state as well as post-closure care and monitoring and ongoing operation of the groundwater remediation system. A portion of the accrual also addresses an outstanding Natural Resource Damage claim by state and federal trustees directed to impacts on marshlands within the plant property.

#### Chambers Works, Deepwater, New Jersey

The Chambers Works complex is located on the eastern shore of the Delaware River in Deepwater, Salem County, New Jersey. The site comprises the former Carneys Point Works in the northern area and the Chambers Works manufacturing area in the southern area. Site operations began in 1892 when the former Carneys Point smokeless gunpowder plant was constructed at the northern end of Carneys Point. Site operations began in the manufacturing area around 1914 and included the manufacture of dyes, aromatics, elastomers, chlorofluorocarbons and tetraethyl lead. Chemours continues to manufacture a variety of fluorochemicals and finished products at Chambers Works. In addition, three tenants operate processes at Chambers Works including steam/electricity generation, industrial gas production and the manufacture of intermediate chemicals. As a result of over 100 years of continuous industrial activity, site soils and groundwater have been impacted by chemical releases.

In response to identified groundwater contamination, a groundwater interceptor well system (IWS) was installed in 1970, which was designed to contain contaminated groundwater and restrict off-site migration. Additional remediation is being completed under a Federal RCRA Corrective Action Permit. The site has been studied extensively over the years and more than 25 remedial actions have been completed to date and engineering and institutional controls put in place to ensure protection of people and the environment.

Remaining work beyond continued operation of the IWS and groundwater monitoring includes completion of a site perimeter sheet pile barrier intended to more efficiently contain groundwater, completion of various targeted studies onsite and in adjacent water bodies to close investigation data gaps and selection and implementation of final remedies under RCRA Corrective Action for various solid waste management units and areas of concern not yet addressed through interim measures.

#### East Chicago, Indiana

East Chicago is a former manufacturing facility owned by Chemours in East Chicago, Lake County, Indiana. The approximate 440-acre site is bounded to the south by the East Branch of the Grand Calumet River, to the east and north by residential and commercial areas and to the west by industrial areas, including a former lead processing facility. The inorganic chemicals unit on site produced various chloride, ammonia and zinc products and inorganic agricultural chemicals beginning in 1892 until 1986. Organic chemical manufacturing began in 1944, consisting primarily of chlorofluorocarbons production. Current operations, including support activities, now cover 28 acres of the site. The remaining business was sold to W.R. Grace Company (Grace) in early 2000, and Grace operates the unit as a tenant. Approximately 172 acres of the site were never developed and are managed by The Nature Conservancy for habitat preservation.

A comprehensive evaluation of soil and groundwater conditions at the site was performed as part of the RCRA corrective action process. Studies of historical site impacts began in 1983 in response to preliminary CERCLA actions undertaken by the U.S. Environmental Protection Agency (EPA). The EPA eventually issued an Administrative Order on Consent for the site in 1997. The order specified that remediation work be performed under RCRA Corrective Action authority. Work has proceeded under the RCRA Corrective Action process since that time.

Subsequent investigations included the preparation of initial environmental site assessments and multiple phases of investigation. In 2002, as an interim remedial measure, two 2,000-foot-long permeable reactive barrier treatment walls were installed along the northern property boundary to address migration of chemicals in groundwater. Since that time, the investigation process has been completed and approved by the EPA and work is in progress to define the final remedy for the site.

#### Pompton Lakes, New Jersey

During the 20th century, blasting caps, fuses and related materials were manufactured at Pompton Lakes, Passaic County, New Jersey. Operating activities at the site were ceased in the mid-1990s. Primary contaminants in the soil and sediments are lead and mercury. Ground water contaminants include volatile organic compounds. Under the authority of the EPA and the New Jersey Department of Environmental Protection, remedial actions at the site are focused on investigating and cleaning up the area. Ground water monitoring at the site is ongoing, and Chemours has installed and continues to install vapor mitigation systems at residences within the ground water plume. In addition, Chemours is further assessing ground water conditions. In June 2015, the EPA issued a modification to the site’s RCRA permit that requires Chemours to dredge mercury contamination from a 36-acre area of the lake and remove sediment from two other areas of the lake near the shoreline. The remediation activities commenced when permits and implementation plans were approved in May 2016, and work on the lake dredging project is expected to be complete in 2018.

#### U.S. Smelter and Lead Refinery, Inc., East Chicago, Indiana

The U.S. Smelter and Lead Refinery, Inc. (USS Lead) Superfund Site is located in the Calumet neighborhood of East Chicago, Lake County, Indiana. The site includes the former USS Lead facility along with nearby commercial, municipal and residential areas. The primary compounds of interest are lead and arsenic which may be found in soils within the impacted area. The EPA is directing and organizing remediation on this site, and Chemours is one of a number of parties working cooperatively with the EPA on the safe and timely completion of this work. DuPont’s former East Chicago manufacturing facility was located adjacent to the site, and DuPont assigned responsibility for the site to Chemours in the 2015 separation agreement.

The USS Lead site was listed on the National Priorities List in 2009. To facilitate negotiations with potentially responsible parties, the EPA divided the residential part of the USS Lead Superfund Site into three zones, referred to as Zone 1, Zone 2 and Zone 3. The division into three zones resulted in Atlantic Richfield Co. and DuPont entering into an agreement in 2014 with the EPA and the State of Indiana to reimburse the EPA’s costs to implement cleanup in Zone 1 and Zone 3. More recently in March 2017, Chemours and three other parties (Atlantic Richfield Co., DuPont and U.S. Metals Refining Co.) entered into an administrative order of consent to reimburse the EPA’s costs to clean up a portion of Zone 2. According to its website, the EPA is continuing its efforts to identify additional parties who might be potentially responsible for the USS Lead site cleanup, including the remainder of Zone 2. Once it has concluded these efforts, the EPA will engage in negotiations with all known viable and liable parties. The updated environmental accrual for USS Lead is based on the Record of Decision (ROD) and Statement of Work currently in place for Zones 1 and 3, as well as the current estimate of Chemours’ share to reimburse the EPA’s Zone 2 cleanup cost under the March 2017 administrative order of consent. The EPA has announced its intent to reconsider the ROD for Zone 1 and the result of that review could increase or decrease

Chemours’ future obligations. In addition, there is uncertainty in the outlook for the remainder of Zone 2 given the EPA’s stated objective to identify additional responsible parties.

### PFOA

See discussion under PFOA in Note 13 to the Interim Consolidated Financial Statements included in this Quarterly Report on Form 10‑Q.

### GenX

See discussion under Environmental in Note 13 to the Interim Consolidated Financial Statements included in this Quarterly Report on Form 10‑Q.

### Non-GAAP Financial Measures

We prepare our financial statements in accordance with generally accepted accounting principles in the U.S. (U.S. GAAP). To supplement our financial information presented in accordance with U.S. GAAP, we provide the following non-GAAP financial measures, Adjusted EBITDA, Adjusted Net Income and Free Cash Flow, in order to clarify and provide investors with a better understanding of the Company’s performance when analyzing changes in our underlying business between reporting periods and provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. We utilize Adjusted EBITDA as the primary measure of segment profitability used by our Chief Operating Decision Maker.

Adjusted EBITDA is defined as income before taxes excluding the following:

- interest expense, depreciation and amortization;
- non-operating pension and other post-retirement employee benefit costs, which represent the components of net periodic pension (income) costs excluding service cost component;
- exchange (gains) losses included in other income (expense), net of the consolidated statement of operations;
- restructuring, asset-related charges and other charges, net;
- asset impairments;
- (gains) losses on sale of business or assets; and
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

Adjusted net income is defined as net income attributable to Chemours adjusted for items excluded from Adjusted EBITDA except interest expense, depreciation and amortization and certain provision for (benefit from) income taxes. Free Cash Flow is defined as cash provided by (used for) operating activities less cash used for purchases of property, plant and equipment as disclosed in the consolidated statements of cash flows.

We believe the presentation of these non-GAAP financial measures, when used in conjunction with U.S. GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company’s operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. In the future, we may incur expenses similar to those eliminated in this presentation. Our presentation of Adjusted EBITDA, Adjusted Net Income and Free Cash Flow should not be construed as an inference that our future results will be unaffected by unusual or infrequently occurring items. The non-GAAP financial measures we use may be defined differently from measures with the same or similar names used by other companies. This analysis, as well as the other information provided in this Quarterly Report on Form 10-Q, should be read in conjunction with the Company’s interim consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q, as well as the Company's consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016.

The following table reconciles Adjusted EBITDA and Adjusted Net Income discussed above to net income (loss) attributable to Chemours for the periods presented:

*(Dollars in millions)*

|  | Three Months Ended June 30, 2017 | 2016 | Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| **Net income (loss) attributable to Chemours** | $161 | $(18) | $311 | $33 |
| Non-operating pension and other post-retirement employee benefit income | (10) | (7) | (18) | (14) |
| Exchange (gains) losses | (2) | 14 | (7) | 20 |
| Restructuring charges | 6 | 9 | 18 | 27 |
| Asset-related charges | 2 | 63 | 2 | 63 |
| Loss (gain) on sale of assets or businesses | 2 | 1 | (14) | (88) |
| Transaction costs 1 | 2 | 12 | 2 | 15 |
| Legal and other charges 2 | 10 | 13 | 17 | 19 |
| Benefit from income taxes relating to reconciling items 3 | (5) | (38) | (3) | (15) |
| **Adjusted Net Income** | 166 | 49 | 308 | 60 |
| Net income attributable to non-controlling interests | — | — | 1 | — |
| Interest expense, net | 55 | 50 | 106 | 106 |
| Depreciation and amortization | 71 | 73 | 142 | 139 |
| All remaining provision for income taxes 3 | 69 | 15 | 90 | 10 |
| **Adjusted EBITDA** | $361 | $187 | $647 | $315 |

1 Includes accounting, legal and bankers transaction fees incurred related to the Company’s strategic initiatives.

2 Includes litigation settlements, water treatment accruals related to PFOA, employee separation costs and lease termination charges.

3 Total of provision for (benefit from) income taxes reconciles to the amount reported in the Interim Consolidated Statements of Operations for the three and six months ended June 30, 2017 and 2016.

## Market risk

As filed, 2,975 characters.

We are exposed to changes in foreign currency exchange rates because of our global operations. As a result, we have assets, liabilities and cash flows denominated in a variety of foreign currencies. We are also exposed to changes in the prices of certain commodities that we use in production. Changes in these rates and commodity prices may have an impact on future cash flow and earnings. We manage these risks through normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. We do not enter into derivative financial instruments for trading or speculative purposes.

Chemours enters into foreign currency forward contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from remeasuring monetary assets and liabilities that Chemours holds which are denominated in non-functional currencies. These derivatives are stand-alone and have not been designated as a hedge. As of June 30, 2017, we had open foreign exchange forward contracts with an aggregate notional U.S. Dollar equivalent of $472 million, the fair value of which amounted to approximately $3 million of net unrealized gain.

In a hypothetical adverse change in the market prices or rates that existed at June 30, 2017, a 10% appreciation of the U.S. Dollar against our outstanding hedged contracts on foreign currencies, such as the Euro and Chinese Yuan, at the currency exchange rates as of June 30, 2017 would increase our net income by approximately $4 million, while a 10% depreciation of the U.S. Dollar against the same hedged currencies would decrease our net income by approximately $5 million.

Chemours hedges its net investment in certain European operations. Changes in the fair value of the hedge in the net investment of certain European operations are recorded in accumulated other comprehensive income (loss). For the three and six months ended June 30, 2017, Chemours did not record any ineffectiveness and recognized a loss of $40 million and $50 million, respectively, on its net investment hedges within accumulated other comprehensive income (loss).

Chemours’ risk management programs and the underlying exposure are closely correlated, such that the potential loss in value for the risk management portfolio described above would be largely offset by the change in value of the underlying exposure. See Note 14 to the Interim Consolidated Financial Statements in Item 1 for further information.

### Additional Information

See Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2016 for additional information on the Company’s utilization of financial instruments and an analysis of the sensitivity of these instruments. There have been no material changes in the market risks previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

## Controls and procedures

As filed, 1,460 characters.

### Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in the Company’s reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the U.S. Securities and Exchange Commission. These controls and procedures also provide reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management, including its Chief Executive Officer (CEO) and Chief Financial Officer (CFO), to allow timely decisions regarding required disclosures.

As of June 30, 2017, the Company’s CEO and CFO, together with management, conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, the CEO and CFO have concluded that these disclosure controls and procedures are effective at the reasonable assurance level.

### Changes in Internal Control over Financial Reporting

There have been no changes in the Company's internal control over financial reporting that occurred during the quarter ended June 30, 2017 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 137 characters.

There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016.

Filed Aug 3, 2017.
Source: SEC EDGAR, the filing index for accession 0001564590-17-015399. Last ingested by Listed: Nov 5, 2026, 19:57 ET. No prices; not investment advice.
